Sponsors gravitate toward large clinical trial site networks for a natural reason: they're an easy way to scale studies fast.
Networks are a smart foundation for a lot of studies, but they work best alongside something else. Independent sites bring a different kind of value: quick adaptability, close attention to detail at the individual site level, and a personal touch that's harder to deliver at scale.
The strongest clinical trial portfolios lean on both.
The upfront math on a network is hard to argue with. Instead of negotiating budgets, timelines, and terms with ten individual clinical research sites, a sponsor negotiates once, and the network's members fall in line behind that agreement.
But, as Jennifer Botte, our director of clinical services, puts it: "This isn't McDonald's, where you're making the Big Mac the same way every time." Every site in a network has its own staff, its own patient population, and its own rhythm.
That variability creates a spread. One site might be a standout performer that lifts the network's numbers. Another might struggle to hit its enrollment targets. The high performer's results can smooth over the full picture when a sponsor looks at aggregate data, but it raises a worthwhile question: would you rather have ten high-performing sites, or ten sites spread across a curve, evened out by an average?
Centralization is a critical selling point of a clinical trial site network. There's one CTMS platform, one framework for data collection, and one set of standards for patient care and regulatory compliance across every site. When it works, it works well, and sponsors rely on that consistency for good reason.
What it also means is that an error travels further. If the source data feeding that shared platform is off, or a data point gets missed, the error doesn't stay contained to one site. It shows up across every site using the same system. Working through that kind of error at scale can mean query resolution delays, audit findings, and timeline slips that touch the whole study.
With an independent site, sponsors, alongside contract research organizations (CROs), get a clear read on performance. There's no network average to look through. The site's numbers around patient recruitment and retention are its own, so a sponsor can trust that a strong result reflects the site itself, not a blend that leans on someone else's proven performance.
That same clarity shows up in how an independent site moves. Agility is easier when performance isn't tangled up with nine other sites. With fewer administrative layers between an issue and a fix, an independent site can catch something and correct it quickly, without waiting on a process built for ten sites instead of one.
That agility also lends itself to a more consultative approach.
As a medium-sized independent site, we've worked with drug and device companies that wanted us to weigh in on trial protocol. Sites at either end of the size spectrum, small or big, often lack that capability. Very large sites are built for execution at scale. Very small sites may have the operational knowledge but lack dedicated experts who can communicate it clearly to a sponsor.
A medium-sized site carries enough experience and resources to offer thoughtful operational input, without the red tape that slows larger organizations down.
Standardized workflows exist for a reason. They give patients a consistent experience regardless of which site in a network they walk into. That consistency matters for data quality and regulatory requirements.
Consistency and personalization aren't the same thing, though, and patients feel the difference.
An independent site layers individualized support on top of that standardized foundation. This includes flexible scheduling that works around a patient's life, transportation help when it's the barrier standing between a patient and a visit, faster turnaround on communication, and a team the patient recognizes and hears from visit after visit.
That kind of support keeps patients engaged in a study and helps drive down dropout. Patient engagement is as key to a study's success as the standardized processes that keep data clean.
At Remington-Davis, we have the experience and resources to run complex studies well without the layers of process that can slow a larger organization down. That same size gives our team room to weigh in on trial design when asked and provide patients with a personalized, meaningful experience.
That's the case for a diversified portfolio. Networks and independent sites, working together, each doing what they do best.
Not automatically. A network's geographic footprint can put a study within reach of more patients on paper, but access depends on whether individual sites have the relationships and reach to bring those patients in the door. A sponsor spread across ten locations still needs those locations to convert proximity into enrollment, which is where site-level recruitment strength matters as much as the size of the map.
Independent sites tend to have deep, long-standing relationships with local healthcare providers and community groups, built over years of working in one place rather than managing dozens. Those relationships often open doors to diverse patient populations that a broader network, moving faster and less locally rooted, has a harder time reaching.
Specialized therapeutic areas, like rare disease or complex device studies, tend to reward sites that can move quickly and think through problems alongside a sponsor rather than simply execute a protocol. A site's depth of experience in a given therapeutic area, combined with the flexibility to adjust as a study evolves, often matters more than the size of its network.
The retention strategies that work best tend to be the ones built around a patient's actual life, including flexible scheduling, transportation support, and a study team the patient recognizes and trusts at every visit. These strategies are a function of a site's ability to pay attention to individual patients rather than manage a study at a distance, which is easier to sustain at a site with fewer patients and locations to track.